Cell membrane-cloaked bioinspired nanoparticles: a novel strategy for breast cancer therapy DOI
Anuja Muley, Abhijeet D. Kulkarni,

Prajakta Mahale

et al.

Journal of Dispersion Science and Technology, Journal Year: 2023, Volume and Issue: 45(7), P. 1351 - 1363

Published: May 21, 2023

Breast cancer is one of the leading cause death in women all around world. Several strategies are utilized for treatment breast & its types. Nanotechnology gaining interest due to advantage nano size, variety carriers, suitable hydrophobic drug loading, controlled and site-specific delivery. Because reproducible synthesis features like shape, ease surface modification, nanoparticles frequently chosen. Further, certain allow adjuvant therapy, which results a synergistic therapeutic outcome. Such nanoparticles, however, detected by immune system eliminated from circulation. Cellular membranes have been studied extensively as potential alternatives augmenting anticancer treatments' biocompatibility targeting abilities. Red blood cells (RBCs), cells, platelets, other identified sources reported membrane-coated delivery systems. Each membrane's distinct ability target tumors biomarkers exploited. Thus, inspired nature cell used camouflage circulation improve retention time tumor ability. These membrane cloaked NPs (CMCNPs) therefore being researched theranoustic, photothermal therapy vaccine development cancer. Here, we covered crucial procedures significant problems involved characterization CMCNPs. This thorough overview modified CMCNPs discusses cloaking techniques, well prospects limitations clinical use

Language: Английский

Amplifying “eat me signal” by immunogenic cell death for potentiating cancer immunotherapy DOI

Yong Xi,

Lijie Chen,

Jian Tang

et al.

Immunological Reviews, Journal Year: 2023, Volume and Issue: 321(1), P. 94 - 114

Published: Aug. 7, 2023

Immunogenic cell death (ICD) is a unique mode of death, which can release immunogenic damage-associated molecular patterns (DAMPs) and tumor-associated antigens to trigger long-term protective antitumor immune responses. Thus, amplifying "eat me signal" during tumor ICD cascade critical for cancer immunotherapy. Some therapies (radiotherapy, photodynamic therapy (PDT), photothermal (PTT), etc.) inducers (chemotherapeutic agents, have enabled initiate and/or facilitate activate Recently, nanostructure-based drug delivery systems been synthesized inducing through combining treatment chemotherapeutic photosensitizers PDT, transformation agents PTT, radiosensitizers radiotherapy, etc., loaded at an appropriate dosage in the designated place time, contributing higher efficiency lower toxicity. Also, immunotherapeutic combination with produce synergetic effects, thus potentiating Overall, our review outlines emerging inducers, nanostructure loading diverse evoke chemoradiotherapy, PTT or agents. Moreover, we discuss prospects challenges harnessing induction-based immunotherapy, highlight significance multidisciplinary interprofessional collaboration promote optimal translation this strategy.

Language: Английский

Citations

40
Nanoparticle‐Mediated STING Activation for Cancer Immunotherapy DOI

Yongjuan Li,

Xinyan Li,

Jinmeng Yi

et al.

Advanced Healthcare Materials, Journal Year: 2023, Volume and Issue: 12(19)

Published: March 11, 2023

Abstract As the first line of host defense against pathogenic infections, innate immunity plays a key role in antitumor immunotherapy. The cyclic GMP‐AMP synthase (cGAS)‐stimulator interferon genes (STING) (cGAS‐STING) pathway has attracted much attention because secretion various proinflammatory cytokines and chemokines. Many STING agonists have been identified applied into preclinical or clinical trials for cancer However, fast excretion, low bioavailability, nonspecificity, adverse effects small molecule limit their therapeutic efficacy vivo application. Nanodelivery systems with appropriate size, charge, surface modification are capable addressing these dilemmas. In this review, mechanism cGAS‐STING is discussed agonists, focusing on nanoparticle‐mediated therapy combined cancers, summarized. Finally, future direction challenges nano‐STING expounded, emphasizing pivotal scientific problems technical bottlenecks hoping to provide general guidance its

Language: Английский

Citations

33
Advances in smart nanotechnology-supported photodynamic therapy for cancer DOI Creative Commons
Guangyao Li, Cong Wang,

Bing‐Hui Jin

et al.

Cell Death Discovery, Journal Year: 2024, Volume and Issue: 10(1)

Published: Nov. 11, 2024

Cancer has emerged as a formidable challenge in the 21st century, impacting society, public health, and economy. Conventional cancer treatments often exhibit limited efficacy considerable side effects, particularly managing advanced stages of disease. Photodynamic therapy (PDT), contemporary non-invasive therapeutic approach, employs photosensitizers (PS) conjunction with precise light wavelengths to selectively target diseased tissues, inducing generation reactive oxygen species ultimately leading cell apoptosis. In contrast conventional therapies, PDT presents lower incidence effects greater precision targeting. The integration intelligent nanotechnology into markedly improved its effectiveness, evidenced by remarkable synergistic antitumor observed utilization multifunctional nanoplatforms PDT. This paper provides concise overview principles underlying PS PDT, while also delving nanomaterial-based context treatment.

Language: Английский

Citations

10
Reinforcing the immunogenic cell death to enhance cancer immunotherapy efficacy DOI
Sihui Yu,

Hongyang Xiao,

Li Ma

et al.

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Journal Year: 2023, Volume and Issue: 1878(5), P. 188946 - 188946

Published: June 28, 2023

Language: Английский

Citations

20
Nanoparticle-mediated immunogenic cell death for cancer immunotherapy DOI

Haolong Qi,

Yuan Li,

Yingjie Geng

et al.

International Journal of Pharmaceutics, Journal Year: 2024, Volume and Issue: 656, P. 124045 - 124045

Published: March 30, 2024

Language: Английский

Citations

7
Novel immunotherapies for breast cancer: Focus on 2023 findings DOI

Huanrong Lan,

Min Chen,

Shi-Ya Yao

et al.

International Immunopharmacology, Journal Year: 2024, Volume and Issue: 128, P. 111549 - 111549

Published: Jan. 23, 2024

Language: Английский

Citations

6
Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms DOI Creative Commons
Aditi Jain,

Alan Barge,

Christopher N. Parris

et al.

Oncogene, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 21, 2024

Abstract Triple-negative breast cancer (TNBC) is a particularly aggressive subtype, characterised by higher incidence in younger women, rapid metastasis, and generally poor prognosis. Patients with TNBC BRCA mutations face additional therapeutic challenges due to the cancer’s intrinsic resistance conventional therapies. Poly (ADP-ribose) polymerase inhibitors (PARPis) have emerged as promising targeted treatment for BRCA-mutated TNBC, exploiting vulnerabilities homologous recombination repair (HRR) pathway. However, despite initial success, efficacy of PARPis often compromised development mechanisms, including HRR restoration, stabilisation replication forks, reduced PARP1 trapping, drug efflux. This review explores latest breakthroughs overcoming PARPi through combination These strategies include integration chemotherapy, immunotherapy, antibody-drug conjugates, PI3K/AKT pathway inhibitors. combinations aim enhance targeting multiple progression pathways. The also discusses evolving role within broader paradigm emphasising need ongoing research clinical trials optimise strategies. By tackling associated exploring novel therapies, this sheds light on future possibilities improving outcomes patients TNBC.

Language: Английский

Citations

6
Photodynamic Therapy-Induced Anti-Tumor Immunity: Influence Factors and Synergistic Enhancement Strategies DOI Creative Commons

Wenxin Chou,

Tianzhen Sun,

Nian Peng

et al.

Pharmaceutics, Journal Year: 2023, Volume and Issue: 15(11), P. 2617 - 2617

Published: Nov. 11, 2023

Photodynamic therapy (PDT) is an approved therapeutic procedure that exerts cytotoxic activity towards tumor cells by activating photosensitizers (PSs) with light exposure to produce reactive oxygen species (ROS). Compared traditional treatment strategies such as surgery, chemotherapy, and radiation therapy, PDT not only kills the primary tumors, but also effectively suppresses metastatic tumors immune response. However, anti-tumor effects induced are influenced several factors, including localization of PSs in cells, concentration, fluence rate light, integrity function. In this review, we systematically summarize influence factors mediated PDT. Furthermore, update on combination other immunotherapy provided. Finally, future directions challenges immunity discussed.

Language: Английский

Citations

16
Zwitterionic Injectable Hydrogel-Combined Chemo- and Immunotherapy Medicated by Monomolecular Micelles to Effectively Prevent the Recurrence of Tumor Post Operation DOI
Rong Wang,

Qiaoying Hu,

Susu Huang

et al.

ACS Applied Materials & Interfaces, Journal Year: 2024, Volume and Issue: 16(3), P. 4071 - 4088

Published: Jan. 9, 2024

Surgical resection remains the most common method of tumor treatment; however, high recurrence and metastasis after surgery need to be solved urgently. Herein, we report an injectable zwitterionic hydrogel based on "thiol-ene" click chemistry containing doxorubicin (DOX) a macrophage membrane (MM)-coated 1-methyl-tryptophan (1-MT)-loaded polyamide-amine dendrimer (P-DOX/1MT) for preventing postoperative tumors. The results indicated that P-DOX/1MT@MM exhibited enhanced recognition uptake by cells induced immunogenic cell death. In mice model, P-DOX/1MT@MM-Gel therapeutic efficiency, which could significantly reduce tumor, including suppressing growth, promoting dendritic maturation, increasing tumor-infiltrating cytotoxic T lymphocytes. mechanism analysis revealed greatly reduces side effects normal tissues improves its effect. 1MT in is released more rapidly, improving suppressor microenvironment sensitivity DOX. Then, DOX effectively eliminatedo residual exerted toxicity. conclusion, this novel combines chemotherapy immunotherapy has property sequential drug release promising strategy

Language: Английский

Citations

5
Nanoparticle targeting cGAS-STING signaling in disease therapy DOI
Zhou Lan,

Yu Huang,

Yuzhang Wu

et al.

Nano Research, Journal Year: 2024, Volume and Issue: 17(8), P. 7315 - 7336

Published: June 15, 2024

Language: Английский

Citations

4